INTERNATIONAL CONGRESS OF
PharmacoGenetics
A Systematic Review of the Role of ABC Transporters in Breast Cancer Drug Resistance: Focus on ABCB1
-
Yekta Rezapour,1 AmirMohammad Ganjali,2 Hossein Javid,3,*
1. Student Research Committee, Varastegan Institute for Medical Sciences, Mashhad, Iran
2. Student Research Committee, Varastegan Institute for Medical Sciences, Mashhad, Iran
3. Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran
- Introduction: Breast cancer ranks among the top causes of cancer-related fatalities in women globally. The inherent or incremental expression of the ABCB1 gene is an essential clinical determinant in cancers like breast, lung, and blood. The ABCB1 gene's expression is linked to cancer patients' survival in the opposite way, which makes it a good target for treatment. Researchers have found that high levels of ABCB1 are connected to chemotherapy resistance in breast, ovarian, and intestinal cancer. Because ABCB1 is involved in drug resistance, addressing it is important in medicine.
- Methods: We looked through the PubMed, Scopus, and ScienceDirect databases in an organized way for papers that came out between 2020 and 2025. We selected 20 studies that met the inclusion criteria for the final analysis after reviewing around 150 papers. These articles had a direct connection to the role of ABCB1 in breast cancer therapy resistance.
- Results: One of the main reasons why cancers become resistant to multi-drug resistance (MDRs) is that ABC family transporters, notably ABCB1 and ABCG2, are too active. These transmitters reduce the amount of medication inside cells by taking chemotherapy drugs out of cancer cells. It reduces the drug's effectiveness, making it less effective overall. Doxorubicin and vincristine are involved. Researchers have found that blocking ABCB1 can make Pakli Taxel work again in breast cancer cells that are resistant to it. New inhibitors, including BLURRED and Elacridar, stop the drug from building up inside the cell by stopping the ABCB1 action. When these inhibitors and PakliaTaxel were used together in preclinical models of breast cancer, the tumor volume went down significantly. Researchers have also demonstrated that the ABCB1 gene extinguisher enhances the sensitivity of resistant cells to treatment.
- Conclusion: ABCB1 targeting is a viable way to navigate around drug resistance in breast cancer and make chemotherapy work better. ABCB1 is a crucial factor in multi-drug resistance (MDR); hence, it is still one of the primary targets for anticancer treatments. Helps with chemotherapy. Early studies have revealed that combining ABCB1 inhibitors with standard chemotherapy regimens has substantial anticancer benefits. However, more research is needed to examine concerns such as medication toxicity and non-specificity.
- Keywords: Drug Resistance, Multiple / Breast Neoplasms / Female / Drug Resistance, Neoplasm
